Nevirapine 200 mg Tablets

Nevirapine 200 mg tablets contain an oral non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of combination antiretroviral therapy for HIV. We offer one 200 mg tablet strength in eight pack sizes, ranging from 20 to 360 tablets. The practical choice is therefore between quantities rather than strengths or pharmaceutical forms.

Package value matters, but it should be considered alongside the prescribed dosing stage, the date of the next clinical review, storage requirements and the amount that can reasonably be used before expiry. This guide compares the available options and explains the medicine's role, usual dosing structure, major safety considerations, Australian prescription status and ordering process.

Available pack sizes and unit value

Every listed option contains the same 200 mg oral tablet. The available quantities are 20, 30, 60, 90, 120, 180, 270 and 360 tablets. The comparison below provides the current price, price per tablet and relative package value for each option without relying on external pharmacy prices or market averages.

A lower price per tablet can make a larger package look attractive, but unit value is only one part of the decision. A package should also correspond to a genuine prescribed need and an appropriate period of use. Compare the total amount payable as well as the per-tablet figure, particularly when a treatment review or possible regimen change is approaching.

Package quantities do not represent different strengths, release types or routes of administration. Choosing 20 rather than 180 tablets changes only the quantity supplied. It does not alter the 200 mg strength or the way each tablet is taken.

How many Nevirapine tablets should you order?

Nevirapine is generally used as ongoing treatment rather than as a short, self-contained course. The suitable quantity depends on the prescription and clinical plan, not simply on which package has the lowest unit cost. Before selecting a pack, consider the following points:

• Prescribed treatment period: compare the quantity with the period for which nevirapine has been prescribed and the date of the next planned review.
• Dosing stage: the usual lead-in and maintenance stages use different numbers of tablets per day, so they should not be treated as interchangeable when estimating supply.
• Continuity: allow enough time to arrange the next authorised supply without accumulating more tablets than the current treatment plan supports.
• Storage and expiry: confirm that the tablets can be stored correctly and used within the expiry period printed on the supplied container.
• Possible treatment changes: resistance results, adverse effects, interactions or other clinical findings may lead a prescriber to review the regimen.

The 20-tablet package should not automatically be treated as a self-directed starter pack, and the largest option should not automatically be treated as the best-value choice. Nevirapine has a specific lead-in schedule, but the amount supplied should still follow the authorised prescription and the broader combination-treatment plan.

Generic naming, Viramune and related medicines

Our catalogue lists this product under the active-ingredient name Nevirapine. Viramune is a brand name for nevirapine that may appear in medical records or treatment discussions. Brand and generic products should be matched by active ingredient, strength, dosage form and release characteristics rather than by name alone. No manufacturer comparison should be inferred where manufacturer details are not supplied.

Nevirapine must be used with other antiretroviral medicines. A complete regimen is selected according to factors such as previous treatment, resistance testing, other health conditions, pregnancy, interactions and tolerance. Products such as Combivir or Epivir may be components of a prescribed combination, but the presence of one related medicine does not by itself define a complete or suitable regimen.

Other antiretroviral options include NNRTIs such as efavirenz, rilpivirine, etravirine and doravirine; integrase inhibitors such as dolutegravir and raltegravir; and protease inhibitors such as darunavir. These medicines differ in dosing, resistance profiles, adverse effects and interactions. They are not direct substitutes to be exchanged without specialist guidance. Our HIV category provides a broader catalogue view, but treatment selection remains a clinical decision.

Nevirapine's established treatment role

HIV uses an enzyme called reverse transcriptase to copy its genetic material inside infected cells. Nevirapine binds to and inhibits this enzyme. Because it acts at a different site from nucleoside reverse transcriptase inhibitors, it is classified as an NNRTI.

Using nevirapine alone would allow resistance to develop quickly, so it is prescribed only as one part of combination antiretroviral therapy. The objective of an effective combination is sustained viral suppression, preservation or recovery of immune function and a reduced risk of HIV-related illness and transmission. Nevirapine does not cure HIV, and treatment should not be stopped or altered solely because symptoms improve.

Nevirapine has an established role in adult HIV treatment and may also be used during pregnancy when clinically appropriate, with the precautions and monitoring required by its Australian product information. It is not suitable for every person. Liver health, previous reactions, current viral resistance and interacting medicines can all affect whether it remains an appropriate option.

Children require dosing based on body weight or body surface area. A fixed 200 mg tablet may be unsuitable for younger or smaller children who need a paediatric formulation and individually calculated dose. Our package options should therefore not be interpreted as paediatric dosing choices.

Practical dosing and the lead-in period

Nevirapine 200 mg tablets are taken by mouth. For adults beginning standard tablet treatment, the usual structure includes a 14-day lead-in period followed by maintenance dosing if no reaction prevents escalation. The prescriber's instructions and the approved product information take priority over this general summary.

The lead-in period is intended to reduce the frequency of rash and must not be shortened by moving to twice-daily dosing early. If a rash develops during the lead-in period, the dose should not be increased until it has resolved and the prescriber has advised what to do. Severe rash, blistering, mouth sores, facial swelling, fever or other systemic symptoms require urgent medical assessment.

The tablets can generally be taken with or without food. Take each dose according to the prescribed schedule and do not double a dose unless specifically instructed. If treatment has been interrupted for several days, contact the prescriber before restarting because the lead-in schedule may need to be repeated. Do not estimate a new schedule from the number of tablets remaining in the pack.

Major safety considerations and interactions

Nevirapine can cause severe and potentially fatal liver and skin reactions, particularly during the first 18 weeks of treatment. Close clinical and laboratory monitoring is especially important during this early period. Monitoring does not eliminate the need to respond promptly to warning symptoms.

• Liver reactions: seek prompt medical advice for yellowing of the skin or eyes, dark urine, pale stools, persistent nausea, abdominal pain, marked tiredness or loss of appetite. Liver tests are generally performed before and during treatment.
• Skin and hypersensitivity reactions: a new rash should be reported promptly. A rash accompanied by fever, blistering, mouth sores, facial swelling, breathing difficulty or signs of organ involvement requires urgent assessment.
• Pregnancy: treatment may continue or begin when a specialist considers it appropriate, but the recognised liver precautions and required monitoring still apply.
• Breastfeeding: nevirapine passes into breast milk, and Australian product information advises mothers receiving it not to breastfeed, including because of the risk of postnatal HIV transmission.
• Diabetes and metabolism: combination antiretroviral treatment has been associated with insulin resistance, raised blood glucose and changes in body-fat distribution. People with diabetes may need closer monitoring.
• Driving: fatigue, drowsiness or dizziness may affect the ability to drive or operate machinery. Avoid these activities when affected.

Nevirapine induces liver enzymes and can alter the concentrations or effects of other medicines. Important examples include rifampicin, some anticonvulsants, certain antifungal and antiviral medicines, St John's wort and hormonal contraceptives. Hormonal contraception may become less reliable, so appropriate additional or alternative contraception should be discussed with a healthcare professional. Provide the prescriber and pharmacist with a complete list of prescription medicines, non-prescription products and supplements before treatment begins and whenever another medicine is added.

Store the tablets at 20°C to 25°C; excursions from 15°C to 30°C are permitted. Keep the bottle tightly closed and protect the tablets from moisture. Storage conditions and the labelled expiry date are particularly relevant when comparing larger package quantities.

Do you need a prescription in Australia?

Yes. Nevirapine is a Prescription Only Medicine classified as Schedule 4 in Australia. It requires a valid prescription from an authorised prescriber. This legal status reflects the need for combination treatment, interaction checks, a controlled lead-in schedule and ongoing monitoring for serious adverse effects.

Regulatory status is separate from catalogue display and price comparison. Being able to review package options or place items into an online ordering process does not remove Australia's prescription requirement. Follow the prescription instructions provided during ordering and ensure that the requested strength and quantity agree with the current authorised treatment plan.

Our support team is available 24/7 by email, online chat and phone for questions about the listed strength, package quantities or order process. Pharmacist support is also available for medicine-related questions. Support can clarify product and ordering information but cannot replace the prescriber responsible for selecting or changing an antiretroviral regimen.

Ordering and delivery

Once the prescription and required quantity are clear, the order can be checked against the current package comparison. A careful review before checkout helps prevent errors involving strength, tablet count or delivery details.

1. Select Nevirapine 200 mg tablets and the package quantity that matches the authorised supply.
2. Review the current total price and per-tablet value shown for that package.
3. Confirm that the delivery name, address and Australian postcode are accurate, and review the order total in AUD.
4. Follow any prescription-verification instructions presented during the order process.
5. Use email, online chat or phone if you need help with an order detail before confirming it.

Delivery timing can depend on the destination and the delivery option available during checkout. Review the delivery information presented for the order rather than relying on a general estimate. After ordering, keep any confirmation details available when contacting our support team about progress or delivery.

Order support can assist with catalogue quantities and transaction details, but it should not be used to make an unapproved dose change or to replace urgent medical advice. Symptoms suggesting a severe liver, skin or allergic reaction require prompt clinical assessment rather than an order enquiry.

A balanced package-value decision

The most useful comparison combines the total package price, per-tablet value and expected period of authorised use. A larger package may offer a lower unit cost, but that does not make it medically preferable. The selected quantity should remain consistent with the prescription, treatment stage, next clinical review and available storage conditions.

Before finalising an order, check:

• that the product is the prescribed 200 mg oral tablet rather than another formulation or release type;
• that the tablet quantity covers an authorised period of treatment without unnecessary excess;
• that any lead-in or restart instructions have been confirmed with the prescriber;
• that recent medicine changes have been checked for interactions;
• that the tablets can be stored in their tightly closed container at the specified temperature and protected from moisture; and
• that the prescription and delivery information are complete and current.

The package-value comparison near the beginning provides the current commercial details, while these clinical and practical checks help place those figures in context. If a package choice remains unclear, contact our support team for ordering assistance or speak with the prescriber or pharmacist about the medically appropriate quantity.